Epigenomics AG represents the values of innovation, excellence, and integrity. The company is dedicated to developing and commercializing innovative solutions for the early detection and diagnosis of cancer through its proprietary biomarker technology. Epigenomics AG is committed to providing reliable and accurate diagnostic products that empower healthcare professionals and improve patient outcomes. With a focus on research and development, the company strives to stay at the forefront of epigenetics and molecular diagnostics. Epigenomics AG believes in fostering collaboration, transparency, and ethical business practices to ensure the highest standards in its operations and interactions with stakeholders.

Epigenomics AG, a leading biotechnology company, is primarily present in various countries and regions around the globe. With its headquarters in Germany, Epigenomics AG has established a strong presence in Europe. Additionally, the company has expanded its operations to North America, including the United States and Canada, where it actively engages in research, development, and commercialization of innovative diagnostic products. Epigenomics AG's global reach also extends to other key markets, catering to healthcare professionals and patients worldwide. This international presence underscores the company's commitment to advancing precision medicine and improving patient outcomes on a global scale.

Epigenomics AG has achieved several significant milestones since its inception. The company gained approval from the U.S. Food and Drug Administration (FDA) for its blood-based colorectal cancer screening test, Epi proColon®. This breakthrough marked a pivotal moment, providing a non-invasive alternative to traditional colonoscopy. Epigenomics AG also secured partnerships with leading diagnostic and pharmaceutical companies, facilitating global distribution of their products. Furthermore, the company's research and development efforts have resulted in numerous patent grants, reinforcing their position as a leader in the field of epigenetics-based diagnostics. These milestones highlight Epigenomics AG's commitment to advancing innovative solutions for cancer screening and detection.

Epigenomics AG is a renowned biotechnology company specializing in cancer diagnosis and personalized medicine. Founded in 1998, the company has since established itself as a global leader in the field of epigenetics. Epigenomics AG focuses on the development and commercialization of innovative diagnostic tests for early detection and prognosis of various types of cancer, including colorectal and lung cancer. With an extensive portfolio of patents and expertise in molecular diagnostics, Epigenomics AG continues to drive advancements in the field, enabling improved patient outcomes and disease management. Its dedication to precision medicine and cutting-edge research positions Epigenomics AG as a vital player in the fight against cancer.

The main competitors of Epigenomics AG in the market include Genomic Health, Exact Sciences Corporation, and Myriad Genetics.

Epigenomics AG is primarily active in the healthcare and biotechnology industries.

The business model of Epigenomics AG is focused on the development and commercialization of innovative tests for the early detection and diagnosis of cancer. Epigenomics AG primarily utilizes its proprietary epigenetic biomarker technology to identify and analyze DNA methylation patterns, which can serve as indicators for various types of cancer. By collaborating with partners and leveraging its expertise in molecular diagnostics, Epigenomics AG aims to provide non-invasive and accurate diagnostic solutions that enable personalized and effective cancer treatment. Through its business model, Epigenomics AG strives to make a positive impact in the field of cancer detection and improve patient outcomes.

Az Epigenomics P/E mutatója -0,72.

Az Epigenomics KUV 1,88.

Az AlleAktien Minőségi Score Epigenomics esetében 3/10.

A várt Epigenomics forgalma 303 000,00 EUR.

A(z) várt Epigenomics nyereség -791 031,96 EUR.

Epigenomics AG is a biotechnology company specializing in the development of diagnostic tests for cancer. The company was founded in 1997 and is headquartered in Berlin, Germany. Epigenomics offers various products and services based on DNA methylation analysis technology, which allows for the quick and precise detection of cancer cells based on DNA changes. One important part of Epigenomics' business model is the development of in vitro diagnostics (IVD) that can be used by doctors and hospitals for cancer diagnosis. The company has developed an IVD platform that can detect specific DNA methylation changes that may indicate the presence of cancer. This platform is capable of diagnosing up to seven different types of cancer, including colorectal, lung, and prostate cancer. Another aspect of Epigenomics' business model is providing services to pharmaceutical companies involved in the development of cancer drugs. Epigenomics offers its customers the opportunity to conduct biomarker tests to study the effectiveness of cancer drugs. Additionally, the company works closely with pharmaceutical companies to validate its technology in clinical trials. Collaboration with other companies and academic institutions in cancer research and other diseases is another important aspect of Epigenomics' business model. Epigenomics works with partners in Europe, North America, Asia, and the Middle East to conduct research projects and clinical trials. Epigenomics is a publicly traded company and generates a portion of its revenue through the sale of products and services. The company also collaborates with various government agencies and organizations to advance its technology in cancer diagnostics. Epigenomics has also filed patents for its technology to protect its intellectual property rights. Overall, Epigenomics has established itself as a leading company in cancer diagnostics, developing innovative technologies and solutions to improve cancer diagnosis. The company has made significant progress in recent years and aims to continue playing a leading role in the field of cancer diagnostics.

A(z) Epigenomics évente alkalommal oszt ki 0 EUR összegű osztalékot.

A Epigenomics esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Epigenomics ISIN kódja: DE000A3H2184.

A Epigenomics WKN-je A3H218.

Az Epigenomics tőzsdei rövidítése ECX.DE.

Az elmúlt 12 hónapban a(z) Epigenomics osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Epigenomics várhatóan 0 EUR összegű osztalékot fog fizetni.

A(z) Epigenomics jelenlegi osztalékhozama .

A(z) Epigenomics negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Epigenomics az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 EUR összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Epigenomics a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Epigenomics által 2024. 12. 17.-án/én fizetett 0 EUR összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 12. 17.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 12. 17. időpontban történt.

2023 évben a Epigenomics 0 EUR összegű osztalékot fizetett ki.

Az Epigenomics osztalékait EUR fizeti ki.